Bloomberg reports on the rise of radiopharmaceutical therapy, highlighting the opportunities and challenges facing one of the fastest-growing areas in cancer treatment.
This article is republished under license from Bloomberg Content Licensing.
Our CEO, Dr. Andrew Cavey, was invited on the pharmaphorum podcast to discuss the evolution of radiopharmaceuticals. As the field rapidly moves from niche to mainstream, the conversation explores key shifts shaping the industry, including the transition to multi-isotope approaches to the growing importance of specialised manufacturing capabilities and a maturing radiopharma ecosystem.
